High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma

53Citations
Citations of this article
56Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background:Interleukin-10 (IL-10) is a inhibiting inflammatory cytokine that plays an important role in immune suppressive microenvironment in multiple myeloma (MM). Whether the level of serum IL-10 could predict treatment response and survival outcomes or not needs to be investigated in MM patients.Methods:The level of IL-10 in serum was measured using enzyme-linked immunosorbent assay in 188 patients with newly diagnosed MM.Results:The best cutoff value for IL-10 in predicting survival is 169.69 pg ml -1 with an area under the curve (AUC) value of 0.747 (P<0.001). In all, 92 patients (48.9%) were classified as high-IL-10 group (>169.96 pg ml -1) and 96 patients (51.1%) as low-IL-10 group (≤169.96 pg ml -1). The overall response rate (ORR) was 79.2% in low-IL-10 group, significantly higher than that in high-IL-10 group (53.3%, P<0.001). Patients in low-IL-10 group had significantly better survival compared with those in high-IL-10 group (3-year PFS rate: 69.3% vs 13.3%, P<0.001; 3-year OS rate: 93.6% vs 51.9%, P<0.001). Multivariate analysis revealed that serum IL-10 level >169.96 pg ml -1 at diagnosis and certain cytogenetic abnormalities were two adverse factors for PFS and OS.Conclusions:Our data suggest that serum IL-10 at diagnosis is a novel, powerful predictor of prognosis for MM.

Cite

CITATION STYLE

APA

Wang, H., Wang, L., Chi, P. D., Wang, W. D., Chen, X. Q., Geng, Q. R., … Lu, Y. (2016). High level of interleukin-10 in serum predicts poor prognosis in multiple myeloma. British Journal of Cancer, 114(4), 463–468. https://doi.org/10.1038/bjc.2016.11

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free